Fundamental Data for TEVA

TEVA PHARM(NSDQ:TEVA)

TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended and immediate release tablets and capsules, creams, ointments, solutions, and suspensions. Key therapeutic areas are the analgesic, anti-infective, cardiovascular, CNS, dermatological and anti-inflammatory categories.

# Employees: 27900

Address: 5 Basel Street P.O. Box 3190,Petach Tikva,,ISR

Phone: 972 3 926 7267

Fax: 972 3 926 7472

Website: www.tevapharm.com

Email:

Sector: Medical

Industry: MED-GENERIC DRG

Executive Officers

Israel Makov (Presi.; C.E.O.)

Rodney Kasan (V.P.; Chief Tech. Off.)

Aharon Agmon (V.P.; Intl. Pharm. Sales)

Haim Benjamini (V.P.; Human Resources)

Dan S. Suesskind (C.F.O.,)

Dividend

Ex-Dividend Date: 11/6/2009

Annual Dividend: $0.48

Current Dividend Yield: $0.91

Dividend Paid (3 months): $0.13

Indicated Dividend: $0.14

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 2/16/2010

Mean EPS (Next Qtr): $0.94

Mean EPS (Year): $3.37

Mean Estimate(Long Term): $20.42

P/E Ratio(Based on EPS estimate): 15.710

Number of Estimates: 20

Shares Performance

Period	TEVA	Compare to S&P
YTD	24.22 %	2.80 %
4 Weeks	4.75 %	-0.55 %
12 Weeks	3.36 %	-3.75 %

Shares Information

Analyst Coverage: Y

Avg Volume: 4088122

Shares Outstanding: 919M

Market Cap: $48.60B

52 Week High: $54.25

52 Week Low: $41.35

P/E Ratio: 16.580

PEG Ratio: 0.770

Split: On 7/1/2004 TEVA split by factor of 2.000

Earnings Performance

EPS Growth in Last Quarter: 7.23 %

EPS Growth in Last Year: 23.61 %

Sales Growth in Last Quarter: 4.41 %

Sales Growth in Last Quarter: 24.91 %

Financials

Qtr Book Value: $2.52

Cash Flow/Share: $16.39

Change in Payout Ratio: 0.000

Price/Sales: 3.750